MME AUDE SERVAIS

Rhumatologue

📍 PARIS CEDEX 15 (75)SalariéRPPS 10001577096

Expérience confirmée

16ans d'exercice (thèse 2010)

🇫🇷 Publications académiques françaises (8)

✨ Profil synthétique

IA · 19/05/2026

MME AUDE SERVAIS est une rhumatologue à Paris, avec une production scientifique importante (225 publications, h-index de 45). Ses recherches portent notamment sur les maladies rénales et les glomérulopathies, ainsi que sur le système du complément dans les maladies. Elle a également travaillé sur la physiologie et la physiopathologie.

Expertises présumées

Néphrologie pédiatrique
Glomérulopathies
Maladies rénales
Génétique des maladies rénales
Pharmacovigilance en rhumatologie
Épidémiologie des maladies rénales
Physiopathologie du système du complément

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Thèses universitaires

Apports de la quantification de la fibrose par analyse d'image couleur pour l'examen anatomopathologique en néphrologie

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022

📚 110 citations🎯 RCR 11.45Top 2% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ABSTRACTApproval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark TEMPO 3:4 trial—marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.

An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis

Kidney international · 2021

📚 50 citations🎯 RCR 4.54Top 9% NIH🔓 Open Access📄 PDF gratuit ↗

Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations

European journal of human genetics : EJHG · 2024

📚 48 citations🎯 RCR 11.07Top 2% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractFour European Reference Networks (ERN-EYE, ERKNet, Endo-ERN, ERN-ITHACA) have teamed up to establish a consensus statement and recommendations for Bardet-Biedl syndrome (BBS). BBS is an autosomal recessive ciliopathy with at least 26 genes identified to date. The clinical manifestations are pleiotropic, can be observed in utero and will progress with age. Genetic testing has progressively improved in the last years prompting for a revision of the diagnostic criteria taking into account clinical Primary and Secondary features, as well as positive or negative molecular diagnosis. This consensus statement also emphasizes on initial diagnosis, monitoring and lifelong follow-up, and symptomatic care that can be provided to patients and family members according to the involved care professionals. For paediatricians, developmental anomalies can be at the forefront for diagnosis (such as polydactyly) but can require specific care, such as for associated neuro developmental disorders. For ophthalmology, the early onset retinal degeneration requires ad hoc functional and imaging technologies and specific care for severe visual impairment. For endocrinology, among other manifestations, early onset obesity and its complications has benefited from better evaluation of eating behaviour problems, improved lifestyle programs, and from novel pharmacological therapies. Kidney and urinary track involvements warrants lifespan attention, as chronic kidney failure can occur and early management might improve outcome. This consensus recommends revised diagnostic criteria for BBS that will ensure certainty of diagnosis, giving robust grounds for genetic counselling as well as in the perspective of future trials for innovative therapies.

Cookies & analyse de trafic

MME AUDE SERVAIS

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal31

Pédiatrie5

Épidémiologie & registres4

Génétique4

Recommandations3

Case report / série1

Pharmacovigilance1

Revue générale1

Vraie vie / RWE1

Datasets & protocoles partagés

Partager cette fiche